Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. All News
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about POLYPHOR AG
10/15POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
10/15La Commission des OPA constate l'absence d'obligation de présenter une offre publique d..
DJ
10/15Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer ..
DJ
10/14Polyphor to Seek Acquisitions
CI
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/27Polyphor AG Announces Executive Changes
CI
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepava..
DJ
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
08/03EQS-ADHOC : Polyphor provides final update on the Phase III FORTRESS study of balixafortid..
DJ
08/03Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Pati..
CI
07/30POLYPHOR : To Layoff 20 Staff After Negative Results From Breast Cancer Treatment Study
MT
07/30EQS-ADHOC : Polyphor to extend period for its strategic evaluation by up to four weeks
DJ
07/16POLYPHOR : to Halt Study of Breast Cancer Combo, Restructure by Up to 29 Positions
MT
07/16EQS-ADHOC : Polyphor provides update on the future of the FORTRESS study of balixafortide ..
DJ
07/16Polyphor AG Provides Update on the Future of the Fortress Study of Balixafortide and An..
CI
06/28GLOBAL MARKETS LIVE : Volkswagen, Daimler, Tesla, Burberry, UBS...
06/28POLYPHOR : Fails in Late-Stage Breast Cancer Drug Trial; Shares Tank 52%
MT
06/28POLYPHOR : provides update on the Phase III FORTRESS study of balixafortide in patients wi..
EQ
06/28Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients W..
GL
06/28Polyphor AG Provides Update on the Phase III FORTRESS Study of Balixafortide in Patient..
CI
06/08EQS-ADHOC : Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel..
DJ
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe Infections ..
EQ
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe Infections ..
GL
06/01POLYPHOR : Balixafortide Shows Antiviral, Anti-Inflammatory Activity Against COVID-19
MT
06/01POLYPHOR : balixafortide demonstrates consistent dual action anti-viral and anti-inflammat..
EQ
06/01Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflam..
GL
06/01Polyphor AG's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inf..
CI
05/18POLYPHOR : to present at the UBS Global Healthcare Virtual Conference
EQ
05/18Polyphor to Present at the UBS Global Healthcare Virtual Conference
GL
04/06POLYPHOR : Annual General Meeting 2021
PU
04/06EQS-ADHOC : Polyphor Annual General Meeting 2021
DJ
03/15POLYPHOR : publishes invitation to Annual General Meeting 2021
PU
03/15POLYPHOR : publishes invitation to Annual General Meeting 2021
EQ
03/05POLYPHOR : FY20 Loss Shrinks to $48 Million
MT
03/05EQS-ADHOC : Polyphor announces financial results -2-
DJ
03/05POLYPHOR : announces financial results for the full-year 2020
EQ
03/05Polyphor Announces Financial Results for the Full-Year 2020
GL
03/05Polyphor AG Provides Clinical Trial Authorization Granted by MHRA to Initiate Phase I T..
CI
03/01POLYPHOR : to present full-year 2020 financial results on March 5
AQ
03/01PRESS RELEASE : Santhera Announces Positive Results with Lonodelestat in Early Phase Cysti..
DJ
02/26EQS-ADHOC : Polyphor to present full-year 2020 financial results on March 5
DJ
02/26POLYPHOR : to present full-year 2020 financial results on March 5
EQ
02/26Polyphor to Present Full-Year 2020 Financial Results on March 5
GL
01/05EQS-ADHOC : Polyphor to take part in panel discussion on novel oncology targets at the Lif..
DJ
01/05Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Part..
GL
2020POLYPHOR : to Commence UK Clinical Trial for Inhaled Antibiotic Murepavadin
MT
2020EQS-ADHOC : Polyphor receives approval to start first-in-human clinical trial of inhaled a..
DJ
2020Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic..
GL
2020Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic..
CI
2020POLYPHOR : announces third positive Data Safety Monitoring Board recommendation to continu..
AQ
2020POLYPHOR : receives an additional USD 2.3 million award from CARB-X to support ongoing dev..
AQ
2020POLYPHOR : Recommended to Continue Balixafortide Study in Breast Cancer Patients
MT
2020EQS-ADHOC : Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommen..
DJ
2020Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to..
GL
2020Polyphor Announces Third Positive Data Safety Monitoring Board Recommendation to Contin..
CI
2020POLYPHOR : Gets $2 Million Funds From CARB-X on Partnership Extension
MT
2020EQS-ADHOC : Polyphor receives an additional USD 2.3 million award from CARB-X to support o..
DJ
2020Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing De..
GL
2020Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing De..
CI
2020POLYPHOR : receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to supp..
AQ
2020POLYPHOR : Cystic Fibrosis Foundation Awards Up to $3.3M to Polyphor for Inhaled Version o..
AQ
2020Cystic Fibrosis Foundation Awards Up to $3.3 Million to Polyphor AG for Inhaled Version..
CI
2020POLYPHOR : Gets $3.3 Million Grant to Advance Trials of Inhaled Antibiotic Murepavadin for..
MT
2020POLYPHOR : receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to supp..
EQ
2020POLYPHOR : receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to sup..
AQ
2020Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to su..
GL
2020Polyphor AG Receives Award of Up to USD 3.3 Million from Cystic Fibrosis Foundation to ..
CI
2020POLYPHOR : to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Trea..
AQ
2020POLYPHOR : to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Trea..
EQ
2020POLYPHOR : completes recruitment in Phase III trial of balixafortide in metastatic breast ..
AQ
1  2  3Next
Upcoming event on POLYPHOR AG
Upcoming sector events